Toll-Like Receptors, Transduction-Effector Pathways, and Disease Diversity: Evidence of an Immunobiological Paradigm Explaining All Human Illness?

REFERENCES

• Kopp E. B., Medzhitov R. The toll-receptor family and control of innate immunity. Curr Opin Immunol. 1999; 11: 13–18
   PubMed Web of Science ®Google Scholar
• Kopp E. B., Medzhitov R. Recognition of microbial infection by Toll-like receptors. Curr Opin Immunol. 2003; 15: 396–401
   PubMed Web of Science ®Google Scholar
• Underhill D. M., Ozinsky A. Toll-like receptors: key mediators of microbe detection. Curr Opin Immunol. 2002; 14: 103–110
   PubMed Web of Science ®Google Scholar
• Schuster J. M., Nelson P. S. Toll receptors: an expanding role in our understanding of human disease. J Leukoc Biol. 2000; 67: 767–773
   PubMed Web of Science ®Google Scholar
• Medzhitov R., Janeway C. A., Jr. Innate immunity: the virtues of a nonclonal system of recognition. Cell 1997; 91: 295–298
   PubMed Web of Science ®Google Scholar
• Beutler B., Hoebe K., Du X., Ulevitch R. J. How we detect microbes and respond to them: the Toll-like receptors and their transducers. J Leukoc Biol 2003; 74: 479–485
   PubMed Web of Science ®Google Scholar
• Janssens S., Beyaert R. Role of Toll-like receptors in pathogen recognition. Clin Microbiol Rev. 2003; 16: 637–646
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay S., Herre J., Brown G. D., Gordon S. The potential for Toll-like receptors to collaborate with other innate immune receptors. Immunology 2004; 112: 521–530
   PubMed Web of Science ®Google Scholar
• Bowie A. G. Translational mini-review series on Toll-like receptors: recent advances in understanding the role of Toll-like receptors in anti-viral immunity. Clin Exp Immunol 2007; 147: 217–26
   PubMed Web of Science ®Google Scholar
• Liu G., Zhao Y. Toll-like receptors and immune regulation: their direct and indirect modulation on regulatory CD4+ CD25+ T cells. Immunology 2007; 122(2)149–156
   Google Scholar
• Kobe B., Deisenhofer J. The leucine rich repeat: a versatile binding motif. Trends Biochem Sci. 1994; 19: 415–421
   PubMed Web of Science ®Google Scholar
• Buchanan S. G., Gay N. J. Structural and functional diversity in the leucine-rich repeat family of proteins. Prog Biophys Mol Biol. 1996; 65: 1–44
   PubMedGoogle Scholar
• O'Neill L. A. Towards an understanding of the signal transduction for interleukin 1. Biochem Biophys Acta. 1995; 1266: 31–44
   PubMed Web of Science ®Google Scholar
• Fearon D. T., Locksley R. M. The instructive role of innate immunity in the acquired immune response. Science 1996; 272: 50–53
   PubMed Web of Science ®Google Scholar
• Medzhitov R., Preston-Hurlburt P., Janeway C. A., Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997; 388: 394–397
   PubMed Web of Science ®Google Scholar
• De Waal Malefyt R., Haanen J., Spits H., et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via down-regulation of class II major histocompatibility complex expression. J Exp Med 1991; 174: 915–924
   PubMed Web of Science ®Google Scholar
• Yssel H., De Waal Maleftt R., Roncarolo M. G., Abrams J. S., Lahesmaa R., Spits H., de Vries J. E. IL-10 is produced by subsets of human CD4+ T cell clones and peripheral blood T cells. J Immunol. 1992; 149: 2378–2384
   PubMed Web of Science ®Google Scholar
• Nemeth Z. H., Hasko G., Vizi E. S. Pyrrolidine dithiocarbamate augments IL-10, inhibits TNF-alpha, MIP-1, IL-12 and nitric oxide production and protects from the lethal effects of endotoxin. Shock 1998; 10: 49–53
   PubMed Web of Science ®Google Scholar
• Brightbill H. D., Plevy S. E., Modlin R. L., Smale S. T. A promonent role for Sp1 during LPS-mediated induction of the IL-10 promoter in macrophages. J Immunol. 2000; 164: 1940–1951
   PubMed Web of Science ®Google Scholar
• Aliprantis A. O., Yang R. B., Mark M. R., et al. Cell activation and apoptosis by bacterial lipoproteins through Toll-liked receptor-2. Science 1999; 285: 736–739
   PubMed Web of Science ®Google Scholar
• O'Neill L. A., Greene C. Signal transduction pathways activated by the IL-1 receptor family: ancient signaling machinery in mammals, insects, and plants. J Leukoc Biol. 1998; 63: 650–657
   PubMed Web of Science ®Google Scholar
• Auron P. E. The interleukin 1 receptor: ligand interactions and signal transduction. Cytokine Growth Factor Rev. 1998; 9: 221–237
   PubMed Web of Science ®Google Scholar
• Medzhitov R., Preston-Hurlburt P., Kopp E., Stadlen A., Chen C., Ghosh S., Janeway C. A., Jr. MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways. Mol Cell 1998; 2: 253–258
   PubMed Web of Science ®Google Scholar
• Muzio M., Ni J., Feng P., Dixit V. M. IRAK (Pelle) family member IRAK-2 and MyD88 as proximal mediators of IL-2 signaling. Science 1997; 278: 1612–1615
   PubMed Web of Science ®Google Scholar
• Cao Z., Henzel W. J., Gao X. IRAK: a kinase associated with the interleukin-1 receptor. Science. 1996; 271: 1128–1131
   PubMed Web of Science ®Google Scholar
• Cao Z., Xiong J., Takeuchi M., Kurama T., Goeddel D. V. TRAF6 is a signal transducer for interleukin-1. Nature 1996; 383: 443–446
   PubMed Web of Science ®Google Scholar
• Lee J., Mira-Aribe L., Ulevitch R. J. TAK1 regulates multiple kinase cascades activated by bacterial lipopolysaccharide. J Leukoc Biol. 2000; 68: 909–915
   PubMed Web of Science ®Google Scholar
• O' Neill L. A., Fitzgerald K. A., Bowie A. G. The Toll-IL-1 receptor adaptor family grows to five members. Trends Immunol. 2003; 24: 286–290
   Google Scholar
• Kobayashi T., Walsh M. C., Choi Y. The role of TRAF6 in signal transduction and the immune response. Microbes Infect. 2004; 6: 1333–1338
   PubMed Web of Science ®Google Scholar
• Woronicz J. D., Gao X., Cao Z., Rothe M., Goeddel D. V. IkappaB kinase-beta: NF-kappaB activation and complex formation with IkappaB kinase-alpha and NIK. Science 1997; 278: 866–869
   PubMed Web of Science ®Google Scholar
• Malinin N. L., Boldin M. P., Kovalenko A. V., Wallach D. MAP3K-related kinase involved in NF-kappaB induction by TNF, CD95 and IL-1. Nature 1997; 385: 540–544
   PubMed Web of Science ®Google Scholar
• Baeuerle P. A. Proinflammatory signaling: last pieces in the NF-kappaB puzzle?. Curr Biol., 8: R19–22; 1998
   Google Scholar
• Underhill D. M. Toll-like receptors: networking for success. Eur J Immunol. 2003; 33: 1767–1775
   PubMed Web of Science ®Google Scholar
• Medzhitov R., Janeway C. A., Jr. Innate immunity: impact on the adaptive immune response. Curr Opin Immunol. 1997; 9: 4–9
   PubMed Web of Science ®Google Scholar
• Ohashi K., Burkhart V., Flohe S., Kolb H. Heat shock protein 60 is a putative endogenous ligand of the Toll-like receptor-4 complex. J Immunol. 2000; 164: 558–561
   PubMed Web of Science ®Google Scholar
• Kawai T., Adachi O., Ogawa T., Takeda K., Akira S. Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity. 1999; 11: 115–122
   PubMed Web of Science ®Google Scholar
• Toshchakov V., Jones B. W., Perera P. Y., Thomas K., Cody M. J., Zhang S., Williams B. R., Major J., Hamilton T. A., Fenton M. J., Vogel S. N. TLR4, but not TLR2, mediates IFN-beta-induced STAT1 alpha/beta-dependent gene expression in macrophages. Nat Immunol. 2002; 3: 392–398
   PubMed Web of Science ®Google Scholar
• Wesche H., Henzel W. J., Shillinglaw W., Li S., Cao Z. MyD88: an adapter that recruits IRAK to the IL-1 receptor complex. Immunity. 1997; 7: 837–847
   PubMed Web of Science ®Google Scholar
• Plevy S. E., Gemberling J. H., Hsu S., Dorner A. J., Smale S. T. Multiple control elements mediate activation of the murine and human interleukin 12 p40 promoters: evidence of functional synergy between C/EBP and Rel proteins. Mol Cell Biol. 1996; 17: 4572–4588
   Google Scholar
• Muzio M., Natoli G., Saccani S., Leverero M., Mantovani A. The human toll signaling pathway: divergence of nuclear factor kappaB and JNK/SAPK activation upstream of tumour necrosis factor receptor-associated factor 6 (TRAF6). J Exp Med. 1998; 187: 2097–2101
   PubMed Web of Science ®Google Scholar
• Brightbill H. D., Modlin R. L. Toll-like receptors: molecular mechanisms of the mammalian immune response. Immunology. 2000; 101: 1–10
   Google Scholar
• Kaisho T., Akira S. Dendritic-cell function in Toll-like receptor and MyD88-knockout mice. Trends Immunol. 2001; 22: 78–83
   PubMed Web of Science ®Google Scholar
• de Smedt T., Pajak B., Muraille E., Lespagnard L., Heinen E., De Baetselier P., Urbain J., Leo O., Moser M. Regulation of dendritic cell numbers and maturation by lipopolysaccharide in vivo. J Exp Med. 1996; 184: 1413–1424
   PubMed Web of Science ®Google Scholar
• Banchereau J., Steinman R. M. Dendritic cells and the control of immunity. Nature 1998; 392: 245–252
   PubMed Web of Science ®Google Scholar
• Mazzoni A., Segal D. M. Controlling the Toll road to dendritic cell polarization. J Leukoc Biol. 2004; 75: 721–730
   PubMed Web of Science ®Google Scholar
• Kadowaki N., Ho S., Antonenko S., de Waal Malefyt R., Kastelein R. A., Bazan F., Liu Y. J. Subsets of dendritic cell precursors express different Toll-like receptors and respond to different microbial antigens. J Exp Med. 2001; 194: 863–869
   PubMed Web of Science ®Google Scholar
• Qi I. L., Denning T. L., Soong L. Differential induction of interleukin-10 and interleukin-12 in dendritic cells by microbial Toll-like receptor activators and skewing of T-cell cytokine profiles. Infect Immun. 2003; 71: 3337–3342
   PubMed Web of Science ®Google Scholar
• Re F., Strominger J. L. Toll-like receptor 2 (TLR2) and TLR4 differentially activate human dendritic cells. J Biol Chem. 2001; 276: 37692–37699
   PubMed Web of Science ®Google Scholar
• Onda H. K., Sakaguchi S., Nakajima C., et al. Selective contribution of IFN-alpha/beta signaling to the maturation of dendritic cells induced by double-stranded RNA or viral infection. Proc Natl Acad Sci. USA 2003; 100: 10872–10877
   Google Scholar
• Iwasaki A., Medzhitov R. Toll-like receptor control of the adaptive immune response. Nat Immunol. 2004; 5: 987–995
   PubMed Web of Science ®Google Scholar
• Froy O. Regulation of mammalian defensin expression by Toll-like receptor-dependent and independent signaling pathways. Cell Microbiol. 2005; 7: 1387–97
   PubMed Web of Science ®Google Scholar
• Marsik C., Mayr F., Cardona F., Derhashnig L., Wagner O. F., Jilma B. Endotoxaemia modulates Toll-like receptors on leukocytes in humans. Br J Haematol. 2003; 121: 653–656
   PubMedGoogle Scholar
• Krutzik S. R., Ochoa M. T., Sieling P. A., Ng Y. W., Legaspi A., Liu P. T., Cole S. T., Godowski P. J., Maeda Y., Sarno E. N., Norgard M. V., Brennan P. J., Akira S., Rea T. H., Modlin R. L. Activation and regulation of Toll-like receptors 2 and 1 in human leprosy. Nat Med. 2003; 9: 525–532
   PubMed Web of Science ®Google Scholar
• Alexopoulou L., Thomas V., Schnare M., Lobet Y., Anguita J., Schoen R. T., Medzhitov R., Fikrig E., Flavell R. A. Hyporesponsiveness to vaccination with Borrelia burgdorferi AspA in humans and in TLR1-and TLR2-deficient mice. Nat Med. 2002; 8: 878–887
   PubMed Web of Science ®Google Scholar
• Agnese D. M., Galvano J. E., Hahm S. J., Coyle S. M., Corbett S. A., Calvano S. E., Lowry S. F. Human Toll-like receptor 4 mutations but not CD14 polymorphisms are associated with an increased risk of Gram-negative infections. J Infect Dis. 2002; 186: 1522–1525
   PubMed Web of Science ®Google Scholar
• Lorenz E., Mira J. P., Frees K. L., Schwartz D. A. Relevance of mutations in the TLR4 receptor in patients with Gram-negative septic shock. Arch Intern Med. 2002; 162: 1028–1032
   PubMed Web of Science ®Google Scholar
• Read R. C., Pullin J., Gregory S., Borrow R., Kaczmarski E. B., di Giovine F. S., Dower S. K., Cannings C., Wilson A. G. A functional polymorphism of Toll-like receptor 4 is not associated with likelihood or severity of meningococcal disease. J Infect Dis. 2001; 184: 640–642
   PubMed Web of Science ®Google Scholar
• Erridge C., Stewart J., Poxton I. R. Monocytes heterozygous for the Asp299Gly and Thr399lle mutations in the Toll-like receptor 4 gene show no deficit in lipopolysaccharide signaling. J Exp Med. 2003; 197: 1787–1791
   PubMedGoogle Scholar
• Von Aulock S., Schroder N. W., Gueininzius K., Traub S., Hoffmann S., Graf K., Dimmeler S., Hartung T., Schumann R. R., Hermann C. Heterozygous Toll-like receptor 4 polymorphism does not influence lipopolysaccharide-induced cytokine release in human whole blood. J Infect Dis. 2003; 188: 938–943
   PubMedGoogle Scholar
• Sing A., Rost D., Tvardovskaia N., Roggenkamp A., Wiedemann A., Kirschning C. J., Aepfelbacher M., Heesemann J. Yersinia V.-antigen exploits Toll-like receptor 2 and CD14 for interleukin-10-mediated immunosuppression. J Exp Med., 196: 1017–1024
   Google Scholar
• Netea M. G., Sutmuller R., Hermann C., Van der Graaf C., Van der Meer J. W. M., Adema G., Kullberg B. J. Toll-like receptor 2 inhibits cellular responses against Candida albicans through pathways mediated by IL-10 and CD4+CD25+ regulatory T cells. Eur Cytokine Netw., 14(Suppl)116, [Abstract]
   Google Scholar
• Jenkins S. J., Hewitson J. P., Jenkins G. R., Mountford A. P. Modulation of the host's immune response by schistosome larvae. Parasite Immunol. 2005; 27: 385–393
   Google Scholar
• Lang T., Mansell A. The negative regulation of Toll-like receptor and associated pathways. Immunol Cell Biol. Aug–Sep. 2007; 85: 425–434
   PubMed Web of Science ®Google Scholar
• Modlin R. L. Activation of Toll-like receptors by microbial lipoproteins: role in host defense. J Allergy Clin Immunol. 2001; 108(4 Suppl)S104–S106
   Google Scholar
• Vabulas R. M., Wagner H., Schild H. Heat shock proteins as ligands of Toll-like receptors. Curr Top Microbiol Immunol. 2002; 270: 169–84
   PubMed Web of Science ®Google Scholar
• McGettrick A. F., Neill A. O'L. Toll-like receptors, key activators of leucocytes and regulator of haematopoiesis. Br J Haematol. 2007; 139: 185–193
   PubMed Web of Science ®Google Scholar
• Salaun B., Romero P., Lebecque S. Toll-like receptors' two-edged sword: when immunity meets apoptosis. Eur J Immunol. 2007; 37: 3311–3118
   PubMed Web of Science ®Google Scholar
• Pasare C., Medzhitov R. Toll-like receptors: balancing host resistance with immune tolerance. Curr Opin Immunol. 2003; 15: 677–682
   PubMed Web of Science ®Google Scholar
• Marshak-Rothstein A. Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol. 2006; 6: 823–835
   PubMed Web of Science ®Google Scholar
• Seibl R., Kyburz D., Lauener R. P., Gay S. Pattern recognition receptors and their involvement in the pathogenesis of arthritis. Curr Opin Rheumatol. 2004; 16: 411–418
   Google Scholar
• Toubi E., Shoenfeld Y. Toll-like receptors and their role in the development of autoimmune diseases. Autoimmunity. 2004; 37: 183–188
   PubMed Web of Science ®Google Scholar
• Radstake T. R., van Lieshout A. W., van Riel P. L., van den Berg W. B., Adema G. J. Dendritic cells, Fc{gamma} receptors, and Toll-like receptors: potential allies in the battle against rheumatoid arthritis. Ann Rheum Dis. 2005; 64: 1532–1538
   Google Scholar
• Kerfoot S. M., Long E. M., Hickey M. J., Andonegui G., Lapointe B. M., Zanardo R. C., Bonder C., James W. G., Robbins S. M., Kubes P. TLR4 contributes to disease-inducing mechanisms resulting in central nervous system autoimmune disease. J Immunol. 2004; 173: 7070–7077
   PubMed Web of Science ®Google Scholar
• Rifkin I. R., Leadbetter E. A., Busconi L., Viglianti G., Marshak-Rothstein A. Toll-like receptors, endogenous ligands, and systemic autoimmune disease. Immunol Rev. 2005; 204: 27–42
   PubMed Web of Science ®Google Scholar
• Bhattacharjee R. N., Akira S. Modifying Toll-like receptor 9 signaling for therapeutic use. Mini Rev Med Chem. 2006; 6: 287–291
   PubMed Web of Science ®Google Scholar
• Popa C., van Lieshout A. W., Roelofs M. F., Geurts A., Moespot P., van Riel L., Calandra T., Sweep F. C., Radstake T. R. MIF production by dendritic cells is differentially regulated by Toll-like receptors and increased during rheumatoid arthritis. Cytokine. 2006; 36: 51–56
   PubMed Web of Science ®Google Scholar
• Candia L., Marquez J., Hernandez C., Zea A. H., Espinoza L. R. Toll-like receptor-2 expression is upregulated in antigen-presenting cells from patients with psoriatic arthritis: a pathogenic role for innate immunity?. J Rheumatol. 2007; 34: 374–379
   PubMed Web of Science ®Google Scholar
• De Rycke L., Vandooren B., Kruithof E., De Keyser F., Veys E. M., Baeten D. Tumor necrosis factor alpha blockade treatment down-modulates the increased systemic and local expression of Toll-like receptor 2 and Toll-like receptor 4 in spondylarthropathy. Arthritis Rheum. 2005; 52: 2146–2158
   PubMedGoogle Scholar
• Yang Z. X., Liang Y., Zhu Y., Li C., Zhang L. Z., Zeng X. M., Zhong R. Q. Increased expression of Toll-like receptor 4 in peripheral blood leucocytes and serum levels of some cytokines in patients with ankylosing spondylitis. Clin Exp Immunol. 2007; 149: 48–55
   Web of Science ®Google Scholar
• Hawn T. R., Wu H., Grossman J. M., Hahn B. H., Tsao B. P., Aderem A. A stop codon polymorphism of Toll-like receptor 5 is associated with resistance to systemic lupus erythematosus. Proc Natl Acad Sci U S A. 2005; 26(30)10593–10597, 102
   Google Scholar
• Papadimitraki E. D., Choulaki C., Koutala E., Bertsias G., Tsatsanis C., Gergianaki I., Raptopoulou A., Kritikos H. D., Mamalaki C., Sidiropoulos P., Boumpas D. T. Expansion of Toll-like receptor 9-expressing B cells in active systemic lupus erythematosus: implications for the induction and maintenance of the autoimmune process. Arthritis Rheum 2006; 54: 3601–3611
   PubMed Web of Science ®Google Scholar
• Christensen S. R., Shupe J., Nickerson K., Kashgarian M., Flavell R. A., Shlomchik M. J. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity. 2006; 25: 417–428, Comment in: Immunity. 25, 397–379
   PubMed Web of Science ®Google Scholar
• Barrat F. J., Meeker T., Chan J. H., Guiducci C., Coffman R. L. Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms. Eur J Immunol. 2007; 37: 3582–3596
   PubMed Web of Science ®Google Scholar
• Nakano S., Morimoto S., Suzuki J., Nozawa K., Amano H., Tokano Y., Takasaki Y. Role of pathogenic auto-antibody production by Toll-like receptor 9 of B cells in active systemic lupus erythematosus. Rheumatology (Oxford) 2008; 47(2)145–149
   Google Scholar
• Park Y., Park S., Yoo E., Kim D., Shin H. Association of the polymorphism for Toll-like receptor 2 with type 1 diabetes susceptibility. Ann N Y Acad Sci. 2004; 1037: 170–174
   PubMed Web of Science ®Google Scholar
• Kolek M. J., Carlquist J. F., Muhlestein J. B., Whiting B. M., Horne B. D., Bair T. L., Anderson J. L. Toll-like receptor 4 gene Asp299Gly polymorphism is associated with reductions in vascular inflammation, angiographic coronary artery disease, and clinical diabetes. Am Heart J. 2004; 148: 1034–1040
   PubMedGoogle Scholar
• Pirie F. J., Pegoraro R., Motala A. A., Rauff S., Rom L., Govender T., Esterhuizen T. M. Toll-like receptor 3 gene polymorphisms in South African Blacks with type 1 diabetes. Tissue Antigens. 2005; 66: 125–130
   PubMedGoogle Scholar
• Zipris D., Lien E., Xie J. X., Greiner D. L., Mordes J. P., Rossini A. A. TLR activation synergizes with Kilham rat virus infection to induce diabetes in BBDR rats. J Immunol. 2005; 174: 131–142
   PubMed Web of Science ®Google Scholar
• Vallois D., Grimm C. H., Avner P., Boitard C., Rogner U. C. The type 1 diabetes locus Idd6 controls TLR1 expression. J Immunol. 2007; 179: 3896–3903
   Google Scholar
• Kim H. S., Han M. S., Chung K. W., Kim S., Kim E., Kim M. J., Jang E., Lee H. A., Youn J., Akira S., Lee M. S. Toll-like receptor 2 senses beta-cell death and contributes to the initiation of autoimmune diabetes. Immunity. 2007; 27: 321–333
   PubMed Web of Science ®Google Scholar
• Lawton J. A., Ghosh P. Novel therapeutic strategies based on Toll-like receptor signaling. Curr Opin Chem Biol. 2003; 7: 446–451
   PubMed Web of Science ®Google Scholar
• Gangloff S. C., Guenounou M. Toll-like receptors and immune response in allergic disease. Clin Rev Allergy Immunol. 2004; 26: 115–125
   Google Scholar
• Velasco G., Campo M., Manrique O. J., Bellou A., He H., Arestides R. S., Schaub B., Perkins D. L., Finn P. W. Toll-like receptor 4 or 2 agonists decrease allergic inflammation. Am J Respir Cell Mol Biol. 2005; 32: 218–224
   PubMed Web of Science ®Google Scholar
• Bauer S., Hangel D., Yu P. Immunobiology of Toll-like receptors in allergic disease. Immunobiology. 2007; 212: 521–533
   PubMed Web of Science ®Google Scholar
• Fukushima A., Yamaguchi T., Ishida W., Fukata K., Ueno H. TLR2 agonist ameliorates murine experimental allergic conjunctivitis by inducing CD4 positive T-cell apoptosis rather than by affecting the Th1/Th2 balance. Biochem Biophys Res Commun. 2006; 339: 1048–1055
   PubMed Web of Science ®Google Scholar
• Bashir M. E., Louie S., Shi H. N., Nagler-Anderson C. Toll-like receptor 4 signaling by intestinal microbes influences susceptibility to food allergy. J Immunol. 2004; 172: 6978–6987
   PubMed Web of Science ®Google Scholar
• Stockfleth E., Trefzer U., Garcia-Bartels C., Wegner T., Schmook T., Sterry W. The use of Toll-like receptor-7 agonist in the treatment of basal cell carcinoma: an overview. Br J Dermatol. 2003; 149(Suppl 66)53–56
   PubMedGoogle Scholar
• Jelaviæ Boraska, Barisiæ T. M., Drmic Hofman I, Boraska V., Vrdoljak E., Peruzoviæ M., Hozo I., Puljiz Z., Terzie J. Microsatelite GT polymorphism in the Toll-like receptor 2 is associated with colorectal cancer. Clin Genet. 2006; 70: 156–160
   Google Scholar
• Fukata M., Chen A., Vamadevan A. S., Cohen J., Breglio K., Krishnareddy S., Hsu D., Xu R., Harpaz N., Dannenberg A. J., Subbaramaiah K., Cooper H. S., Itzkowitz S. H., Abreu M. T. Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology. 2007; 133: 1869–1881
   PubMed Web of Science ®Google Scholar
• Zheng S. L., Augustsson-Bälter K., Chang B., Hedelin M., Li L., Adami H. O., Bensen J., Li G., Johnasson J. E., Turner A. R., Adams T. S., Meyers D. A., Isaacs W. B., Xu J., Grönberg H. Sequence variants of Toll-like receptor 4 are associated with prostate cancer risk: results from the CAncer Prostate in Sweden Study. Cancer Res. 2004; 64: 2918–2922
   PubMed Web of Science ®Google Scholar
• Sun J., Wiklund F., Zheng S. L., Chang B., Bälter K., Li L., Johansson J. E., Li G., Adami H. O., Liu W., Tolin A., Turner A. R., Meyers D. A., Isaacs W. B., Xu J., Grönberg H. Sequence variants in Toll-like receptor gene cluster (TLR6-TLR1-TLR10) and prostate cancer risk. J Natl Cancer Inst. 2005; 97: 525–532
   PubMedGoogle Scholar
• Chen Y. C., Giovannucci E., Lazarus R., Kraft P., Ketkar S., Hunter D. J. Sequence variants of Toll-like receptor 4 and susceptibility to prostate cancer. Cancer Res. 2005; 65: 11771–11778
   PubMed Web of Science ®Google Scholar
• Cheng I., Plummer S. J., Casey G., Witte J. S. Toll-like receptor 4 genetic variation and advanced prostate cancer risk. Cancer Epidemiol Biomarkers Prev. 2007; 16: 352–355
   PubMed Web of Science ®Google Scholar
• Tahara T., Arisawa T., Wang F., Shibata T., Nakamura M., Sakata M., Hirata I., Nakano H. Toll-like receptor 2 -196 to 174del polymorphism influences the susceptibility of Japanese people to gastric cancer. Cancer Sci. 2007; 98: 1790–1794
   PubMed Web of Science ®Google Scholar
• Hold G. L., Rabkin C. S., Chow W. H., Smith M. G., Gammon M. D., Risch H. A., Vaughan T. L., McColl K. E., Lissowska J., Zatonski W., Schoenberg J. B., Blot W. J., Mowat N. A., Fraumeni J. F., Jr., El-Omar E. M. A functional polymorphism of Toll-like receptor 4 gene increases risk of gastric carcinoma and its precursors. Gastroenterology. 2007; 132: 905–912
   PubMed Web of Science ®Google Scholar
• Spaner D. E., Shi Y., White D., Mena J., Hammond C., Tomic J., He L., Tomai M. A., Miller R. L., Booth J., Radvanyi L. Immunomodulatory effects of Toll-like receptor-7 activation on chronic lymphocytic leukemia cells. Leukemia. 2006; 20: 286–295
   PubMed Web of Science ®Google Scholar
• Chicoine M. R., Zahner M., Won E. K., Kalra R. R., Kitamura T., Perry A., Higashikubo R. The in vivo antitumoral effects of lipopolysaccharide against glioblastoma multiforme are mediated in part by Toll-like receptor 4. Neurosurgery. 2007; 60: 372–380
   PubMed Web of Science ®Google Scholar
• Nieters A., Beckmann L., Deeg E., Becker N. Gene polymorphisms in Toll-like receptors, interleukin-10, and interleukin-10 receptor alpha and lymphoma risk. Genes Immun. 2006; 7: 615–624
   PubMed Web of Science ®Google Scholar
• Li J., Song W., Czerwinski D. K., Varghese B., Uematsu S., Akira S., Krieg A. M., Levy R. Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself. J Immunol. 2007; 179: 2493–2500
   PubMed Web of Science ®Google Scholar
• Kim W. Y., Lee J. W., Choi J. J., Choi C. H., Kim T. J., Kim B. G., Song S. Y., Bae D. S. Increased expression of Toll-like receptor 5 during progression of cervical neoplasia. Int J Gynecol Cancer. 2008; 18(2)300–305
   Google Scholar
• Lee J. W., Choi J. J., Seo E. S., Kim M. J., Kim W. Y., Choi C. H., Kim T. J., Kim B. G., Song S. Y., Bae D. S. Increased Toll-like receptor 9 expression in cervical neoplasia. Mol Carcinog. 2007; 46: 941–917
   Google Scholar
• Pashenkov M., Goëss G., Wagner C., Hörmann M., Jandl T., Moser A., Britten C. M., Smolle J., Koller S., Mauch C., Tantcheva-Poor I., Grabbe S., Loquai C., Esser S., Franckson T., Schneeberger A., Haarmann C., Krieg A. M., Stingl G., Wagner S. N. Phase II trial of a Toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma. J Clin Oncol. 2006; 24: 5716–5724
   PubMed Web of Science ®Google Scholar
• Kiechl S., Wiedermann C. J., Willeit J. Toll-like receptor 4 and atherogenesis. Ann Med. 2003; 35: 164–171
   PubMed Web of Science ®Google Scholar
• Shinohara M., Hirata K., Yamashita T., Takaya T., Sasaki N., Shiraki R., Ueyama T., Emoto N., Inoue N., Yokoyama M., Kawashima S. Local overexpression of Toll-like receptors at the vessel wall induces atherosclerotic lesion formation: synergism of TLR2 and TLR4. Arterioscler Thromb Vasc Biol. 2007; 27: 2384–2391
   Google Scholar
• Pasterkamp G., Van Keulen J. K., De Kleijn D. P. Role of Toll-like receptor 4 in the initiation and progression of atherosclerotic disease. Eur J Clin Invest. 2004; 34: 328–334
   PubMed Web of Science ®Google Scholar
• Arroyo-Espliguero R., Avanzas P., Jeffery S., Kaski J. C. CD14 and Toll-like receptor 4: a link between infection and acute coronary events?. Heart. 2004; 90: 983–988
   PubMedGoogle Scholar
• Stoll L. L., Denning G. M., Weintraub N. L. Endotoxin, TLR4 signaling and vascular inflammation: potential therapeutic targets in cardiovascular disease. Curr Pharm Des. 2006; 12: 4229–4245
   PubMed Web of Science ®Google Scholar
• Mullick A. E., Tobias P. S., Curtiss L. K. Modulation of atherosclerosis in mice by Toll-like receptor 2. J Clin Invest. 2005; 115: 3149–3156
   PubMed Web of Science ®Google Scholar
• Schoneveld A. H., Oude Nijhuis M. M., van Middelaar B., Laman J. D., de Kleijn D. P., Pasterkamp G. Toll-like receptor 2 stimulation induces intimal hyperplasia and atherosclerotic lesion development. Cardiovasc Res. 2005; 66: 162–169
   PubMed Web of Science ®Google Scholar
• Favre J., Musette P., Douin-Echinard V., Laude K., Henry J. P., Arnal J. F., Thuillez C. Richard VToll-like receptors 2-deficient mice are protected against postischemic coronary endothelial dysfunction. Arterioscler Thromb Vasc Biol. 2007; 27: 1064–1071
   PubMed Web of Science ®Google Scholar
• Ameziane N., Beillat T., Verpillat P., Chollet-Martin S., Aumont M. C., Seknadji P., Lamotte M., Lebret D., Ollivier V., de Prost D. Association of the Toll-like receptor 4 gene Asp299Gly polymorphism with acute coronary events. Arterioscler Thromb Vasc Biol. 2003; 23: e61–64
   PubMed Web of Science ®Google Scholar
• Geng H. L., Lu H. Q., Zhang L. Z., Zhang H., Zhou L., Wang H., Zhong R. Q. Increased expression of Toll like receptor 4 on peripheral-blood mononuclear cells in patients with coronary arteriosclerosis disease. Clin Exp Immunol. 2006; 143: 269–273
   PubMed Web of Science ®Google Scholar
• Holloway J. W., Yang I. A., Ye S. Variation in the Toll-like receptor 4 gene and susceptibility to myocardial infarction. Pharmacogenet Genomics. 2005; 15: 15–21
   PubMedGoogle Scholar
• Karikó K., Weissman D., Welsh F. A. Inhibition of Toll-like receptor and cytokine signaling–a unifying theme in ischemic tolerance. Cereb Blood Flow Metab 2004; 24: 1288–1304
   PubMedGoogle Scholar
• McInturff J. E., Modlin R. L., Kim J. The role of Toll-like receptors in the pathogenesis and treatment of dermatological disease. J Invest Dermatol. 2005; 125: 1–8
   PubMed Web of Science ®Google Scholar
• Baker B. S., Ovigne J. M., Powles A. V., Corcoran S., Fry L. Normal keratinocytes express Toll-like receptors (TLRs) 1, 2 and 5: modulation of TLR expression in chronic plaque psoriasis. Br J Dermatol. 2003; 148: 670–679
   PubMed Web of Science ®Google Scholar
• Kim J., Ochoa M. T., Krutzik S. R., Takeuchi O., Uematsu S., Legaspi A. J., Brightbill H. D., Holland D., Cunliffe W. J., Akira S., Sieling P. A., Godowski P. J., Modlin R. L. Activation of Toll-like receptor 2 in acne triggers inflammatory cytokine responses. J Immunol. 2002; 169: 1535–1541
   PubMed Web of Science ®Google Scholar
• Ueta M., Sotozono C., Inatomi T., Kojima K., Tashiro K., Hamuro J., Kinoshita S. Toll-like receptor 3 gene polymorphisms in Japanese patients with Stevens-Johnson syndrome. Br J Ophthalmol. 2007; 91: 962–965
   PubMed Web of Science ®Google Scholar
• Cario E., Podolsky D. K. Differential alteration in intestinal epithelial cell expression of Toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect Immun. 2000; 68: 7010–7017
   PubMed Web of Science ®Google Scholar
• Cario E. Toll-like receptors and intestinal defence: molecular basis and therapeutic implications. Expert Rev Mol Med. 2003; 5: 1–15
   Google Scholar
• Franchimont D., Vermeire S., El Housni H., Pierik M., Van Steen K., Gustot T., Quertinmont E., Abramowicz M., Van Gossum A., Devière J., Rutgeerts P. Deficient host-bacteria interactions in inflammatory bowel disease? The Toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn's disease and ulcerative colitis. Gut. 2004; 53: 987–992
   PubMed Web of Science ®Google Scholar
• Hong J., Leung E., Fraser A. G., Merriman T. R., Vishnu P., Krissansen G. W. TLR2, TLR4 and TLR9 polymorphisms and Crohn's disease in a New Zealand Caucasian cohort. J Gastroenterol Hepatol. 2007; 22: 1760–1766
   PubMed Web of Science ®Google Scholar
• Brand S., Staudinger T., Schnitzler F., Pfennig S., Hofbauer K., Dambacher J., Seiderer J., Tillack C., Konrad A., Crispin A., Göke B., Lohse P., Ochsenkühn T. The role of Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms and CARD15/NOD2 mutations in the susceptibility and phenotype of Crohn's disease. Inflamm Bowel Dis. 2005; 11: 645–652
   PubMed Web of Science ®Google Scholar
• Netea M. G., Kullberg B. J., de Jong D. J., Franke B., Sprong T., Naber T. H., Drenth J. P., Van der Meer J. W. NOD2 mediates anti-inflammatory signals induced by TLR2 ligands: implications for Crohn's disease. Eur J Immunol. 2004; 34: 2052–2059
   PubMed Web of Science ®Google Scholar
• Katakura K., Lee J., Rachmilewitz D., Li G., Eckmann L., Raz E. Toll-like receptor 9-induced type I IFN protects mice from experimental colitis. J Clin Invest. 2005; 115: 695–702
   PubMed Web of Science ®Google Scholar
• Vijay-Kumar M., Sanders C. J., Taylor R. T., Kumar A., Aitken J. D., Sitaraman S. V., Neish A. S., Uematsu S., Akira S., Williams I. R., Gewirtz A. T. Deletion of TLR5 results in spontaneous colitis in mice. J Clin Invest. 2007; 117: 3909–3921
   PubMed Web of Science ®Google Scholar
• Abreu M. T. Immunologic regulation of Toll-like receptors in gut epithelium. Curr Opin Gastroenterol. 2003; 19: 559–564
   Google Scholar
• Oostenbrug L. E., Drenth J. P., de Jong D. J., Nolte I. M., Oosterom E., van Dullemen H. M., van der Linde K., te Meerman G. J., van der Steege G., Kleibeuker J. H., Jansen P. L. Association between Toll-like receptor 4 and inflammatory bowel disease. Inflamm Bowel Dis. 2005; 11: 567–575
   PubMed Web of Science ®Google Scholar
• Pierik M., Joossens S., Van Steen K., Van Schuerbeek N., Vlietinck R., Rutgeerts P., Vermeire S. Toll-like receptor-1, -2, and -6 polymorphisms influence disease extension in inflammatory bowel diseases. Inflamm Bowel Dis. 2006; 12: 1–8
   PubMed Web of Science ®Google Scholar
• Frolova L., Drastich P., Rossmann P., Klimesova K., Tlaskalova-Hogenova H. Expression of Toll-like receptor 2 (TLR2), TLR4, and CD14 in biopsy samples of patients with inflammatory bowel diseases: upregulated expression of TLR2 in terminal ileum of patients with ulcerative colitis. J Histochem Cytochem. 2008; 56(3)267–274
   Web of Science ®Google Scholar
• Szebeni B., Veres G., Dezsõfi A., Rusai K., Vannay A., Mraz M., Majorova E., Arató A. Increased expression of Toll-like receptor (TLR) 2 and TLR4 in the colonic mucosa of children with inflammatory bowel disease. Clin Exp Immunol. 2008; 151: 34–41
   PubMed Web of Science ®Google Scholar
• Szebeni B., Veres G., Dezsofi A., Rusai K., Vannay A., Bokodi G., Vásárhelyi B., Korponay-Szabó I. R., Tulassay T., Arató A. Increased mucosal expression of Toll-like receptor (TLR)2 and TLR4 in coeliac disease. J Pediatr Gastroenterol Nutr. 2007; 45: 187–193
   PubMed Web of Science ®Google Scholar
• van Westerloo D. J., Weijer S., Bruno M. J., de Vos A. F., Van't Veer C., van der Poll T. Toll-like receptor 4 deficiency and acute pancreatitis act similarly in reducing host defense during murine Escherichia coli peritonitis. Crit Care Med. 2005; 33: 1036–1043
   PubMedGoogle Scholar
• Leaphart C. L., Cavallo J., Gribar S. C., Cetin S., Li J., Branca M. F., Dubowski T. D., Sodhi C. P., Hackam D. J. A critical role for TLR4 in the pathogenesis of necrotizing enterocolitis by modulating intestinal injury and repair. J Immunol. 2007; 179: 4808–4820
   PubMed Web of Science ®Google Scholar
• Takii Y., Nakamura M., Ito M., Yokoyama T., Komori A., Shimizu-Yoshida Y., Nakao R., Kusumoto K., Nagaoka S., Yano K., Abiru S., Ueki T., Matsumoto T., Daikoku M., Taniguchi K., Fujioka H., Migita K., Yatsuhashi H., Nakashima M., Harada M., Ishibashi H. Enhanced expression of type I interferon and Toll-like receptor-3 in primary biliary cirrhosis. Lab Invest. 2005; 85: 908–820
   PubMed Web of Science ®Google Scholar
• Wang A. P., Migita K., Ito M., Takii Y., Daikoku M., Yokoyama T., Komori A., Nakamura M., Yatsuhashi H., Ishibashi H. Hepatic expression of Toll-like receptor 4 in primary biliary cirrhosis. J Autoimmun. 2005; 25: 85–91
   PubMed Web of Science ®Google Scholar
• Zuo G., Gong J., Liu C., Wu C., Li S., Dai L. Synthesis of Toll-like receptor 4 in Kupffer cells and its role in alcohol-induced liver disease. Chin Med J (Engl). 2003; 116: 297–300
   PubMed Web of Science ®Google Scholar
• Wang L., Xu J. B., Wu H. S., Zhang J. X., Zhang J. H., Tian Y., Wang C. Y. The relationship between activation of TLR4 and partial hepatic ischemia/reperfusion injury in mice. Hepatobiliary Pancreat Dis Int. 2006; 5: 101–104
   PubMedGoogle Scholar
• Prince J. M., Levy R. M., Yang R., Mollen K. P., Fink M. P., Vodovotz Y., Billiar T. R. Toll-like receptor-4 signaling mediates hepatic injury and systemic inflammation in hemorrhagic shock. J Am Coll Surg. 2006; 202: 407–417
   PubMed Web of Science ®Google Scholar
• Saturnino S. F., Andrade M. V. Toll-like receptors, new horizons in sepsis. Curr Mol Med. 2007; 7: 522–531
   Google Scholar
• Amorim Zuany-C., Hastewell J., Walker C. Toll-like receptors as potential therapeutic targets for multiple diseases. Nat Rev Drug Discov. 2002; 1: 797–807
   Google Scholar
• Chang J. H., McCluskey P. J., Wakefield D. Toll-like receptors in ocular immunity and the immunopathogenesis of inflammatory eye disease. Br J Ophthalmol. 2006; 90: 103–108
   PubMed Web of Science ®Google Scholar
• Berdeli A., Celik H. A., Ozyürek R., Dogrusoz B., Aydin H. H. TLR-2 gene Arg753Gln polymorphism is strongly associated with acute rheumatic fever in children. J Mol Med. 2005; 83: 535–541
   PubMed Web of Science ®Google Scholar
• Fukusaki T., Ohara N., Hara Y., Yoshimura A., Yoshiura K. Evidence for association between a Toll-like receptor 4 gene polymorphism and moderate/severe periodontitis in the Japanese population. J Periodontal Res. 2007; 42: 541–545
   Google Scholar
• Emonts M., Veenhoven R. H., Wiertsema S. P., Houwing-Duistermaat J. J., Walraven V., de Groot R., Hermans P. W., Sanders E. A. Genetic polymorphisms in immunoresponse genes TNFA, IL6, IL10, and TLR4 are associated with recurrent acute otitis media. Pediatrics. 2007; 120: 814–823
   PubMed Web of Science ®Google Scholar
• Pabst S., Baumgarten G., Stremmel A., Lennarz M., Knüfermann P., Gillissen A., Vetter H., Grohé C. Toll-like receptor (TLR) 4 polymorphisms are associated with a chronic course of sarcoidosis. Clin Exp Immunol. 2006; 143: 420–426
   Google Scholar
• Kielian T. Toll-like receptors in central nervous system glial inflammation and homeostasis. J Neurosci Res. 2006; 83: 711–730
   PubMed Web of Science ®Google Scholar
• Jackson A. C., Rossiter J. P., Lafon M. Expression of Toll-like receptor 3 in the human cerebellar cortex in rabies, herpes simplex encephalitis, and other neurological diseases. J Neurovirol. 2006; 12: 229–234
   Web of Science ®Google Scholar
• Chen K., Iribarren P., Hu J., Chen J., Gong W., Cho E. H., Lockett S., Dunlop N. M., Wang J. M. Activation of Toll-like receptor 2 on microglia promotes cell uptake of Alzheimer disease-associated amyloid beta peptide. J Biol Chem. 2006; 281: 3651–3659
   PubMed Web of Science ®Google Scholar
• Nessa B. N., Tanaka T., Kamino K., Sadik G., Ansar A. B., Kimura R., Tanii H., Okochi M., Morihara T., Tagami S., Kudo T., Takeda M. Toll-like receptor 3 mediated hyperphosphorylation of tau in human SH-SY5Y neuroblastoma cells. Psychiatry Clin Neurosci. 2006; 60(Suppl 1)S27–33
   Google Scholar
• Walter S., Letiembre M., Liu Y., Heine H., Penke B., Hao W., Bode B., Manietta N., Walter J., Schulz-Schuffer W., Fassbender K. Role of the Toll-like receptor 4 in neuroinflammation in Alzheimer's disease. Cell Physiol Biochem. 2007; 20: 947–56
   PubMed Web of Science ®Google Scholar
• Prinz M., Garbe F., Schmidt H., Mildner A., Gutcher I., Wolter K., Piesche M., Schroers R., Weiss E., Kirschning C. J., Rochford C. D., Brück W., Becher B. Innate immunity mediated by TLR9 modulates pathogenicity in an animal model of multiple sclerosis. J Clin Invest. 2006; 116: 456–456
   PubMed Web of Science ®Google Scholar
• Guo L. H., Schluesener H. J. The innate immunity of the central nervous system in chronic pain: the role of Toll-like receptors. Cell Mol Life Sci. 2007; 64: 1128–1136
   PubMed Web of Science ®Google Scholar
• Krediet T. G., Wiertsema S. P., Vossers M. J., Hoeks S. B., Fleer A., Ruven H. J., Rijkers G. T. Toll-like receptor 2 polymorphism is associated with preterm birth. Pediatr Res. 2007; 62(4)474–476
   Google Scholar
• Chaudhuri N., Dower S. K., Whyte M. K., Sabroe I. Toll-like receptors and chronic lung disease. Clin Sci (Lond). 2005; 109: 125–33
   Web of Science ®Google Scholar
• Eder W., Klimecki W., Yu L., von Mutius E., Riedler J., Braun-Fahrländer C., Nowak D., Martinez F. D. ALEX Study Team. Toll-like receptor 2 as a major gene for asthma in children of European farmers. J Allergy Clin Immunol. 2004; 113: 482–488
   PubMed Web of Science ®Google Scholar
• Tantisira K., Klimecki W. T., Lazarus R., Palmer L. J., Raby B. A., Kwiatkowski D. J., Silverman E., Vercelli D., Martinez F. D., Weiss S. T. Toll-like receptor 6 gene (TLR6): single-nucleotide polymorphism frequencies and preliminary association with the diagnosis of asthma. Genes Immun. 2004; 5: 343–346
   PubMed Web of Science ®Google Scholar
• Phipps S., Lam C. E., Foster P. S., Matthaei K. I. The contribution of Toll-like receptors to the pathogenesis of asthma. Immunol Cell Biol. 2007; 85: 463–470
   PubMed Web of Science ®Google Scholar
• Revets H., Pynaert G., Grooten J., De Baetselier P., Lipoprotein I. a TLR2/4 ligand modulates Th2-driven allergic immune responses. J Immunol. 2005; 174: 1097–1103
   Google Scholar
• Hoffjan S., Stemmler S., Parwez Q., Petrasch-Parwez E., Arinir U., Rohde G., Reinitz-Rademacher K., Schultze-Werninghaus G., Bufe A., Epplen J. T. Evaluation of the Toll-like receptor 6 Ser249Pro polymorphism in patients with asthma, atopic dermatitis and chronic obstructive pulmonary disease. BMC Med Genet. 2005; 6: 34
   PubMedGoogle Scholar
• Lazarus R., Raby B. A., Lange C., Silverman E. K., Kwiatkowski D. J., Vercelli D., Klimecki W. J., Martinez F. D., Weiss S. T. Toll-like receptor 10 genetic variation is associated with asthma in two independent samples. Am J Respir Crit Care Med. 2004; 170: 594–600
   PubMed Web of Science ®Google Scholar
• Droemann D., Goldmann T., Tiedje T., Zabel P., Dalhoff K., Schaaf B. Toll-like receptor 2 expression is decreased on alveolar macrophages in cigarette smokers and COPD patients. Respir Res. 2005; 6: 68
   PubMed Web of Science ®Google Scholar
• Rohde G., Klein W., Arinir U., Hagedorn M., Duerig N., Bauer T. T., Gillissen A., Schultze-Werninghaus G., Epplen T J. Association of the ASP299GLY TLR4 polymorphism with COPD. Respir Med. 2006; 100: 892–896
   Google Scholar
• Hauber H. P., Tulic M. K., Tsicopoulos A., Wallaert B., Olivenstein R., Daigneault P., Hamid Q. Toll-like receptors 4 and 2 expression in the bronchial mucosa of patients with cystic fibrosis. Can Respir J. 2005; 12: 13–8
   PubMedGoogle Scholar
• Zhang X., Shan P., Jiang G., Cohn L., Lee P. J. Toll-like receptor 4 deficiency causes pulmonary emphysema. J Clin Invest. 2006; 116: 3050–3059
   PubMed Web of Science ®Google Scholar
• Anders H. J., Schlöndorff D. Toll-like receptors: emerging concepts in kidney disease. Curr Opin Nephrol Hypertens. 2007; 16: 177–183, Ann Med., 35, 164–71, 2003
   Google Scholar
• Patole P. S., Pawar R. D., Lichtnekert J., Lech M., Kulkarni O. P., Ramanjaneyulu A., Segerer S., Anders H. J. Coactivation of Toll-like receptor-3 and -7 in immune complex glomerulonephritis. J Autoimmun. 2007; 29: 52–9
   PubMedGoogle Scholar
• Liu B., Yang Y., Dai J., Medzhitov R., Freudenberg M. A., Zhang P. L., Li Z. TLR4 up-regulation at protein or gene level is pathogenic for lupus-like autoimmune disease. J Immunol. 2006; 177: 6880–6888
   PubMed Web of Science ®Google Scholar
• Mollen K. P., Anand R. J., Tsung A., Prince J. M., Levy R. M., Billiar T. R. Emerging paradigm: Toll-like receptor 4-sentinel for the detection of tissue damage. Shock. 2006; 26: 430–437
   PubMed Web of Science ®Google Scholar
• Zhang Z., Schluesener H. J. Mammalian Toll-like receptors: from endogenous ligands to tissue regeneration. Cell Mol Life Sci. 2006; 63: 2901–2907
   PubMed Web of Science ®Google Scholar
• Dybdahl B., Wahba A., Lien E., Flo T. H., Waage A., Qureshi N., Sellevold O. F., Espevik T., Sundan A. Inflammatory response after open heart surgery: release of heat-shock protein 70 and signaling through Toll-like receptor-4. Circulation. 2002; 105: 685–690
   PubMed Web of Science ®Google Scholar
• Tang S. C., Arumugam T. V., Xu X., Cheng A., Mughal M. R., Jo D. G., Lathia J. D., Siler D. A., Chigurupati S., Ouyang X., Magnus T., Camandola S., Mattson M. P. Pivotal role for neuronal Toll-like receptors in ischemic brain injury and functional deficits. Proc Natl Acad Sci U S A. 2007; 104: 13798–13803
   PubMed Web of Science ®Google Scholar
• Lehnardt S., Lehmann S., Kaul D., Tschimmel K., Hoffmann O., Cho S., Krueger C., Nitsch R., Meisel A., Weber J. R. Toll-like receptor 2 mediates CNS injury in focal cerebral ischemia. J Neuroimmunol. 2007; 190: 28–33
   PubMed Web of Science ®Google Scholar
• Murphy T. J., Paterson H. M., Kriynovich S., Zang Y., Kurt-Jones E. A., Mannick J. A., Lederer J. A. Linking the “two-hit” response following injury to enhanced TLR4 reactivity. J Leukoc Biol. 2005; 77: 16–23
   Google Scholar
• Barber R. C., Aragaki C. C., Rivera-Chavez F. A., Purdue G. F., Hunt J. L., Horton J. W. TLR4 and TNF-alpha polymorphisms are associated with an increased risk for severe sepsis following burn injury. J Med Genet. 2004; 41: 808–813
   PubMed Web of Science ®Google Scholar
• Shimamoto A., Pohlman T. H., Shomura S., Tarukawa T., Takao M., Shimpo H. Toll-like receptor 4 mediates lung ischemia-reperfusion injury. Ann Thorac Surg. 2006; 82: 2017–2023, Comment in: Ann Thorac Surg., 82, 2023, 2006
   PubMed Web of Science ®Google Scholar
• Santin I., Bilbao J. R., de Nanclares G. P., Calvo B., Castaño L. No association of TLR2 and TLR4 polymorphisms with type I diabetes mellitus in the Basque population. Ann N Y Acad Sci. 2006; 1079: 268–72
   Google Scholar
• Santin I., Castellanos-Rubio A., Hualde I., Castaño L., Vitoria J. C., Bilbao J. R. Toll-like receptor 4 (TLR4) gene polymorphisms in celiac disease. Tissue Antigens. 2007; 70: 495–8
   PubMedGoogle Scholar
• Na K. S., Kim T. H., Rahman P., Peddle L., Choi C. B., Inman R. D. Analysis of single nucleotide polymorphisms in Toll-like receptor 4 shows no association with ankylosing spondylitis in a Korean population. Rheumatol Int. 2007
   Google Scholar
• Sheedy F. J., Marinou I., O'Neill L. A., Wilson A. G. The Mal/TIRAP S180L and TLR4 G299D polymorphismsare not associated with susceptibility to or severity of rheumatoid arthritis. Ann Rheum Dis. 2008
   Google Scholar
• Demirci F. Y., Manzi S., Ramsey-Goldman R., Kenney M., Shaw P. S., Dunlop -C., Thomas M., Kao A. H., Rhew E. Y., Bontempo F., Kammerer C., Kamboh M. I. Association study of Toll-like receptor 5 (TLR5) and Toll-like receptor 9 (TLR9) polymorphisms in systemic lupus erythematosus. J Rheumatol. 2007; 34: 1708–1711, Comment in: J Rheumatol., 34: 1641–1642, 2007
   Google Scholar
• Netea M. G., van der Graaf C., van der Meer J. W. M., Kullberg B. J. Toll-like receptors and the host defense against microbial pathogens: bringing specificity to the innate-immune system. J Leukoc Biol. 2004; 75: 749–755
   PubMed Web of Science ®Google Scholar
• Oda K., Kitano H. A comprehensive map of the Toll-like receptor signaling network. Mol Syst Biol. 2006; 2: 1–20
   Google Scholar